UB Paderborn / Katalog / Suche / in CDI

Design and rationale for the Patient and Provider Assessment of Lipid Management (PALM) registry

The American heart journal, 2015-11, Vol.170 (5), p.865-871

2015

Volltextzugriff (PDF)

PREVALENCE AND MANAGEMENT OF PATIENT-REPORTED SYMPTOMS ON STATIN THERAPY: INSIGHTS FROM THE PATIENT AND PROVIDER ASSESSMENT OF LIPID MANAGEMENT (PALM) REGISTRY

Journal of the American College of Cardiology, 2016-04, Vol.67 (13), p.1894-1894

2016

Volltextzugriff (PDF)

CONTRASTING US PATIENTS WITH A FILL VERSUS A PRESCRIPTION FOR ALIROCUMAB: EARLY EVIDENCE FROM ADMINISTRATIVE CLAIMS, EMR AND LAB DATA

Journal of the American College of Cardiology, 2017, Vol.69 (11), p.1713-1713

2017

Volltextzugriff (PDF)

A Quantitative Systems Pharmacology Platform to Investigate the Impact of Alirocumab and Cholesterol-Lowering Therapies on Lipid Profiles and Plaque Characteristics

Gene Regulation and Systems Biology, 2017-06, Vol.2017 (11), p.1177625017710941-1177625017710941

2017

Volltextzugriff (PDF)

Quantifying Importance of Major Risk Factors for Coronary Heart Disease

Circulation (New York, N.Y.), 2019-03, Vol.139 (13), p.1603-1611

2019

Volltextzugriff (PDF)

Prescribing Patterns of Proprotein Convertase Subtilisin-Kexin Type 9 Inhibitors in Eligible Patients With Clinical Atherosclerotic Cardiovascular Disease or Heterozygous Familial Hypercholesterolemia

The American journal of cardiology, 2018-05, Vol.121 (10), p.1155-1161

2018

Volltextzugriff (PDF)

Lipid management in contemporary community practice: Results from the Provider Assessment of Lipid Management (PALM) Registry

The American heart journal, 2017-11, Vol.193, p.84-92

2017

Volltextzugriff (PDF)

PATIENTS’ PERCEIVED VERSUS PREDICTED CARDIOVASCULAR DISEASE RISK: CHALLENGES FOR SHARED DECISION-MAKING IN CHOLESTEROL MANAGEMENT

Journal of the American College of Cardiology, 2016, Vol.67 (13), p.1929-1929

2016

Volltextzugriff (PDF)

Abstract 203: Gender Differences in PCSK9 Inhibitor Prescribing

Circulation Cardiovascular quality and outcomes, 2017-03, Vol.10 (suppl_3)

2017

Volltextzugriff (PDF)

UNDERSTANDING THE PREDICTORS OF ACHIEVING LDL-C TARGETS WHEN ADDING EZETIMIBE IN HIGH RISK PATIENTS

Journal of the American College of Cardiology, 2017-03, Vol.69 (11), p.1703-1703

2017

Volltextzugriff (PDF)

STATIN UTILIZATION PATTERNS DURING INPATIENT ADMISSIONS FOR ACUTE CORONARY SYNDROME (ACS)

Journal of the American College of Cardiology, 2017-03, Vol.69 (11), p.229-229

2017

Volltextzugriff (PDF)

CONTRASTING US PATIENTS WITH A FILL VERSUS A PRESCRIPTION FOR ALIROCUMAB: EARLY EVIDENCE FROM ADMINISTRATIVE CLAIMS, EMR AND LAB DATA

Journal of the American College of Cardiology, 2017-03, Vol.69 (11), p.1713-1713

2017

Volltextzugriff (PDF)

Alirocumab efficacy and safety by race and ethnicity: Analysis from 3 ODYSSEY phase 3 trials

Journal of clinical lipidology, 2019-07, Vol.13 (4), p.586-593.e5

2019

Volltextzugriff (PDF)

Association of Patient Perceptions of Cardiovascular Risk and Beliefs on Statin Drugs With Racial Differences in Statin Use: Insights From the Patient and Provider Assessment of Lipid Management Registry

JAMA cardiology, 2018-08, Vol.3 (8), p.739

2018

Volltextzugriff (PDF)

Statin Utilization Patterns and Outcomes for Patients with Acute Coronary Syndrome During and Following Inpatient Admissions

Cardiovascular drugs and therapy, 2018-06, Vol.32 (3), p.273-280

2018

Volltextzugriff (PDF)

ALIROCUMAB IN HIGH-RISK PATIENTS WITH BASELINE LDL-C ≥160 MG/DL: FINDINGS FROM THE COMPASSIONATE USE PROGRAM

Journal of the American College of Cardiology, 2017-03, Vol.69 (11), p.155-155

2017

Volltextzugriff (PDF)

Abstract #402 Achievement of Pre-Defined Lipid Goals in Individuals with Type 2 Diabetes Randomized To Alirocumab or Ezetimibe

Endocrine practice, 2018-04, Vol.24, p.96

2018

Volltextzugriff (PDF)

ACHIEVEMENT OF PRE-DEFINED LIPID GOALS IN INDIVIDUALS WITH TYPE 2 DIABETES RANDOMIZED TO ALIROCUMAB OR EZETIMIBE

Endocrine practice, 2018-04, Vol.24, p.96-96

2018

Volltextzugriff (PDF)

An open-label, single-arm, phase II clinical trial of RP1, an enhanced potency oncolytic herpes virus, combined with nivolumab in four solid tumor types: Initial results from the skin cancer cohorts

Journal of clinical oncology, 2020-05, Vol.38 (15_suppl), p.e22050-e22050

2020

Volltextzugriff (PDF)

Prevalence and Management of Symptoms Associated With Statin Therapy in Community Practice: Insights From the PALM (Patient and Provider Assessment of Lipid Management) Registry

Circulation Cardiovascular quality and outcomes, 2018-03, Vol.11 (3), p.e004249-e004249

2018

Volltextzugriff (PDF)

CONTEMPORARY PATTERNS OF LIPID TESTING IN PRIMARY AND SECONDARY PREVENTION PATIENTS: INSIGHTS FROM THE PALM REGISTRY

Journal of the American College of Cardiology, 2017-03, Vol.69 (11), p.1695-1695

2017

Volltextzugriff (PDF)

Alirocumab in high-risk patients: Observations from the open-label expanded use program

Journal of clinical lipidology, 2018-05, Vol.12 (3), p.662-668

2018

Volltextzugriff (PDF)

Statin Utilization Patterns Following An Acute Coronary Syndrome (ACS) Event

Journal of clinical lipidology, 2017-05, Vol.11 (3), p.805-806

2017

Volltextzugriff (PDF)

PATIENTS’ PERCEIVED VERSUS PREDICTED CARDIOVASCULAR DISEASE RISK: CHALLENGES FOR SHARED DECISION-MAKING IN CHOLESTEROL MANAGEMENT

Journal of the American College of Cardiology, 2016-04, Vol.67 (13), p.1929-1929

2016

Volltextzugriff (PDF)

Prevalence and Management of Symptoms Associated with Statin Therapy in Community Practice: Insights from the Patient and Provider Assessment of Lipid Management (PALM) Registry

Circulation Cardiovascular quality and outcomes, 2018-03, Vol.11 (3), p.e004249-e004249

2018

Volltextzugriff (PDF)

Menü

Weitere Dienste

Einstellungen

Design and rationale for the Patient and Provider Assessment of Lipid Management (PALM) registry

PREVALENCE AND MANAGEMENT OF PATIENT-REPORTED SYMPTOMS ON STATIN THERAPY: INSIGHTS FROM THE PATIENT AND PROVIDER ASSESSMENT OF LIPID MANAGEMENT (PALM) REGISTRY

CONTRASTING US PATIENTS WITH A FILL VERSUS A PRESCRIPTION FOR ALIROCUMAB: EARLY EVIDENCE FROM ADMINISTRATIVE CLAIMS, EMR AND LAB DATA

A Quantitative Systems Pharmacology Platform to Investigate the Impact of Alirocumab and Cholesterol-Lowering Therapies on Lipid Profiles and Plaque Characteristics

Quantifying Importance of Major Risk Factors for Coronary Heart Disease

Prescribing Patterns of Proprotein Convertase Subtilisin-Kexin Type 9 Inhibitors in Eligible Patients With Clinical Atherosclerotic Cardiovascular Disease or Heterozygous Familial Hypercholesterolemia

Lipid management in contemporary community practice: Results from the Provider Assessment of Lipid Management (PALM) Registry

PATIENTS’ PERCEIVED VERSUS PREDICTED CARDIOVASCULAR DISEASE RISK: CHALLENGES FOR SHARED DECISION-MAKING IN CHOLESTEROL MANAGEMENT

Abstract 203: Gender Differences in PCSK9 Inhibitor Prescribing

UNDERSTANDING THE PREDICTORS OF ACHIEVING LDL-C TARGETS WHEN ADDING EZETIMIBE IN HIGH RISK PATIENTS

STATIN UTILIZATION PATTERNS DURING INPATIENT ADMISSIONS FOR ACUTE CORONARY SYNDROME (ACS)

CONTRASTING US PATIENTS WITH A FILL VERSUS A PRESCRIPTION FOR ALIROCUMAB: EARLY EVIDENCE FROM ADMINISTRATIVE CLAIMS, EMR AND LAB DATA

Alirocumab efficacy and safety by race and ethnicity: Analysis from 3 ODYSSEY phase 3 trials

Association of Patient Perceptions of Cardiovascular Risk and Beliefs on Statin Drugs With Racial Differences in Statin Use: Insights From the Patient and Provider Assessment of Lipid Management Registry

Statin Utilization Patterns and Outcomes for Patients with Acute Coronary Syndrome During and Following Inpatient Admissions

ALIROCUMAB IN HIGH-RISK PATIENTS WITH BASELINE LDL-C ≥160 MG/DL: FINDINGS FROM THE COMPASSIONATE USE PROGRAM

Abstract #402 Achievement of Pre-Defined Lipid Goals in Individuals with Type 2 Diabetes Randomized To Alirocumab or Ezetimibe

ACHIEVEMENT OF PRE-DEFINED LIPID GOALS IN INDIVIDUALS WITH TYPE 2 DIABETES RANDOMIZED TO ALIROCUMAB OR EZETIMIBE

An open-label, single-arm, phase II clinical trial of RP1, an enhanced potency oncolytic herpes virus, combined with nivolumab in four solid tumor types: Initial results from the skin cancer cohorts

Prevalence and Management of Symptoms Associated With Statin Therapy in Community Practice: Insights From the PALM (Patient and Provider Assessment of Lipid Management) Registry

CONTEMPORARY PATTERNS OF LIPID TESTING IN PRIMARY AND SECONDARY PREVENTION PATIENTS: INSIGHTS FROM THE PALM REGISTRY

Alirocumab in high-risk patients: Observations from the open-label expanded use program

Statin Utilization Patterns Following An Acute Coronary Syndrome (ACS) Event

PATIENTS’ PERCEIVED VERSUS PREDICTED CARDIOVASCULAR DISEASE RISK: CHALLENGES FOR SHARED DECISION-MAKING IN CHOLESTEROL MANAGEMENT

Prevalence and Management of Symptoms Associated with Statin Therapy in Community Practice: Insights from the Patient and Provider Assessment of Lipid Management (PALM) Registry

Suchergebnisse filtern